Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta- thalassemia and other chronic anemias.
Deferasirox is marketed as Exjade, Desirox, Defrijet, Desifer, and Jadenu.
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which is subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
The major global manufacturers of Dillaros are Novartis, Cipla, Natco Pharma and Sun Pharma, among which Novartis is the industry leader with a market share of around 99%. North America is the largest spending region, with 30 per cent of the market, followed by Europe with 25 per cent.

The global Deferasirox market was valued at US$ 2612.3 million in 2020 and is expected to reach US$ 3554.9 million by the end of 2027, growing at a CAGR of 4.5% during 2021-2027.
This report focuses on Deferasirox volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Deferasirox market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Deferasirox Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
500 mg/Tablet
250 mg/Tablet
125 mg/Tablet
Others

Segment by Application
Transfusional Iron Overload
NTDT Caused Iron Overload

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Novartis
Cipla
Natco Pharma
Sun Pharma